Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Imugene ( (AU:IMU) ) has provided an announcement.
Imugene Limited has notified the market of the issue of 400 unquoted options expiring on 30 June 2028 with an exercise price of $0.86, issued on 16 February 2026. These options, documented via an Appendix 3G, form part of previously announced transactions and are not quoted, nor intended to be quoted, on the ASX, indicating a minor adjustment to the company’s capital structure rather than a shift in strategic direction.
The small scale and unquoted nature of the new options suggest limited immediate impact on existing shareholders but reflect ongoing use of equity-based instruments within Imugene’s broader financing or incentive frameworks. By maintaining transparent disclosure of such issuances, Imugene continues to align with ASX regulatory requirements while fine-tuning its balance between dilution and capital or incentive needs.
The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.24 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is an Australian biotechnology company listed on the ASX under the code IMU. The company operates in the life sciences sector, focusing on developing biopharmaceutical products, though this specific notice centers on its capital structure rather than its clinical or commercial portfolio.
Average Trading Volume: 1,379,106
Technical Sentiment Signal: Sell
Current Market Cap: A$78.77M
For a thorough assessment of IMU stock, go to TipRanks’ Stock Analysis page.